News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tau Therapeutics, LLC to Address World Drug Repositioning Congress


9/11/2012 9:58:02 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC, a company repositioning and developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that President and CEO Andrew J. Krouse will speak at the World Drug Repositioning Congress in London, England, September 11-13, 2012. Tau Therapeutics is repositioning former hypertension drug, mibefradil dihydrochloride, in its Interlaced Therapy™ method to treat solid tumor cancers.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES